Starmer has just wasted his time in China. We need a proper system on foreign investment

AstraZeneca announced an £11bn package of investment in China, but the article argues the deal benefits China and shareholders more than the UK and heightens dependency on Chinese supply chains. The piece highlights security risks from Chinese technology and infrastructure investments (citing Huawei, Mingyang, CGN/Hinkley and a 2020 £2bn 5G reversal), criticises the current UK investment-screening architecture under the National Security and Investment Act and the ISU’s repositioning in the Cabinet Office reporting to the Chancellor of the Duchy of Lancaster (Darren Jones MP), and urges creation of a cross-departmental screening body akin to CFIUS to prioritise national security. Public scepticism is noted (YouGov: 41% see the relationship as bad for UK security), framing the government’s China outreach as politically risky and a potential policy area that could affect technology, infrastructure and defence-related investments.

Analysis

Market structure: The AstraZeneca £11bn China capex is an immediate win for Chinese manufacturing and AZN shareholders (scale manufacturing, lower COGS), while UK domestic tech/infrastructure and supply‑chain resilience are the losers. Expect concentration of advanced pharma capacity in China to raise supplier pricing power there and depress global marginal prices for commoditized drug manufacturing; FX and political risk will increase volatility in sterling and UK equity risk premia over the next 3–12 months.

Risk assessment: Tail risks include a UK regulatory backlash (NSI reform or ad‑hoc blocks) that could idle projects or force divestments within 6–18 months, and Chinese retaliation (market access restrictions) that could remove future China revenue — both >10% EBITDA shock scenarios for exposed firms. Near term (days–weeks) price moves will be driven by headlines and polls; medium term (3–12 months) by legislative action; long term (1–3 years) by re‑shoring and capex reallocation.

Trade implications: Tactical trades should hedge political/FX rather than pure operational outlooks. Volatility in AZN and GBP creates option opportunities; defence and domestic manufacturing stand to gain from higher security spending and perceived decoupling — rotate 2–4% of equity exposure into high‑quality UK defence names and hedge China‑sensitive healthcare risk with puts or pair shorts.

Contrarian angle: The consensus focuses on geopolitics but underestimates operational upside to AZN margins from vertically integrated Chinese manufacturing (cost reduction visible within 12–24 months). If UK screening tightens excessively, more firms will accelerate capital allocation to China — a potential multi‑quarter positive for Chinese industrial suppliers and a buying opportunity in oversold Western suppliers once headlines fade.

Key Decisions for Investors

• Establish a 1.0–2.0% long position in AZN (AstraZeneca) funded from cash; simultaneously buy a 6‑month 10% OTM put and sell a 6‑month 25% OTM put (ratio 1:1) to cap downside while retaining upside from the £11bn China build-out.
• Initiate a 2.0–3.0% overweight in UK defence: buy BAE Systems (BA.L) or equivalent ETF exposure (horizon 6–18 months); target total return +15–25% if UK security spending guidance tightens within 6 months.
• Short 10‑year Gilt futures (size = 0.5% NAV equivalent) if 10y gilt yield breaks +20bps intraday from levels at time of trade; set stop if yield reverses by 15bps. Rationale: higher perceived political risk and higher defence spending → larger gilt issuance/yields.
• Buy 3‑month GBPUSD 25‑delta puts (size 0.5–1.0% NAV) if GBPUSD trades below 1.24 or implied vol <30% — asymmetric hedge against sterling weakness from political fallout.
• Trigger‑based rule: if the UK government announces formal NSI reform to a cross‑departmental committee within 60 days, close AZN put hedge and add up to +1.0% incremental long AZN (expect headline risk to be permanently reduced and operational upside to materialise over 12–24 months).